|
SRRD expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.33066907387547E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.6251444634463E-12 |
| Normal-vs-Stage2 |
1.76350000047343E-07 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
3.235900E-02 |
| Stage1-vs-Stage3 |
2.797800E-01 |
| Stage1-vs-Stage4 |
1.54553999999196E-05 |
| Stage2-vs-Stage3 |
9.276400E-03 |
| Stage2-vs-Stage4 |
2.14349999999586E-05 |
| Stage3-vs-Stage4 |
2.101400E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
4.59043913991763E-12 |
| Normal-vs-Asian |
3.10862446895044E-15 |
| Caucasian-vs-AfricanAmerican |
1.257380E-01 |
| Caucasian-vs-Asian |
9.394800E-01 |
| AfricanAmerican-vs-Asian |
1.623630E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62492241884138E-12 |
| Male-vs-Female |
4.176000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
6.198400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.010000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.456600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.721370E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.373600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.156180E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.081210E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.171920E-02 |
| Classical-VS-Follicular |
5.779900E-02 |
| Classical-VS-Other |
6.596100E-02 |
| Classical-VS-Normal |
1.62492241884138E-12 |
| Tall-VS-Follicular |
9.248400E-04 |
| Tall-VS-Other |
2.169000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
6.087600E-02 |
| Follicular-VS-Normal |
2.13949968852489E-11 |
| Other-VS-Normal |
4.39370000049344E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.572600E-04 |
|
|
